Table 2.
Association between long-term immunosuppression and clinical outcomes in COVID-19
| Invasive mechanical ventilation | In-hospital death | |
|---|---|---|
| Immunosuppressed group, n (%) | ||
| Entire cohort (n=16 494) | 1520 (9%) | 2334 (14%) |
| Matched cohort (n=12 841) | 1089 (8%) | 1743 (14%) |
| Non-immunosuppressed group, n (%) | ||
| Entire cohort (n=206 081) | 13 220 (6%) | 19 467 (9%) |
| Matched cohort (n=29 386) | 2730 (9%) | 3564 (12%) |
| Comparison of immunosuppressed vs non-immunosuppressed adults | ||
| Unadjusted regression in entire cohort, HR (95% CI) | 1·36 (1·29–1·43) | 1·05 (1·01–1·10) |
| Unadjusted regression in matched cohort, HR (95% CI) | 0·88 (0·82–0·94) | 1·01 (0·96–1·07) |
| Propensity score matching with doubly robust adjustment, HR (95% CI) | 0·89 (0·83–0·96) | 0·97 (0·91–1·02) |
| E-value | 1·50 | 1·21 |
| Propensity score matching with doubly robust adjustment among male patients (n=18 798), HR (95% CI) | 0·86 (0·78–0·95) | 0·97 (0·90–1·05) |
| Propensity score matching with doubly robust adjustment among female patients (n=23 199), HR (95% CI) | 0·89 (0·81–0·99) | 0·95 (0·88–1·04) |
HR=hazard ratio.